COST ANALYSIS OF BRANDED VERSUS GENERIC ANTI-DIABETIC DRUGS USED FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN A TERTIARY CARE HOSPITAL

Author:

SARANNYA RAVI ,LIYA ROSLIN JOSEPH ,SREELAKSHMI VENUGOPAL

Abstract

Objectives: This study aims to assess the percentage cost variation among branded anti-diabetic drugs prescribed in a tertiary care hospital with its generic equivalent. Methods: A cross-sectional study was performed in a tertiary care hospital among 51 diabetic patients attending the endocrinology outpatient department. Demographic data and details of anti-diabetic drugs prescribed were collected from case sheets. Costs of branded anti-diabetic drugs were obtained from the current index of medical specialties April–July 2023 and their generic equivalents from Janaushadhi price list 2023. The percentage cost variation of these drugs per prescription was determined. Results: The mean age of the patients included in the study was 58.12, with 23 male and 28 female participants. Thirty-eight (74.5%) prescriptions contained oral hypoglycemic agent (OHA) alone, and 12 (23.54%) contained insulin and OHA. Metformin–glimepiride combination was the most common drug prescribed. The mean cost of the branded anti-diabetic drugs per prescription per day was 28.15±13.85 and the estimated mean cost of their generic equivalent was 12.10±6.68. A 135.61% cost variation was observed for the antidiabetic drug prescriptions studied. Conclusion: In this study, it was observed that there is a significant cost variation among branded and generic anti-diabetic drugs.

Publisher

Innovare Academic Sciences Pvt Ltd

Reference21 articles.

1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Duncan BB, Stein C, et al. IDF diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022 Jan 1;183:109119.

2. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021.

3. U.S. Food and Drug Administration. Generic Drug Facts. U.S. FDA. Available from: https://www.fda.gov/drugs/generic-drugs/generic-drugs-facts [Last assessed on 2024 May 18].

4. Jan Aushadhi. Pradhan Mantri Jan Aushadhi Yojana (PMJY). Available from: https://janaushadhi.gov.in/pmjy.aspx [Last assessed on 2024 May 18].

5. Chaudhary RK, Philip MJ, Santhosh A, Karoli SS, Bhandari R, Ganachari MS. Health economics and effectiveness analysis of generic anti-diabetic medication from Jan Aushadhi: An ambispective study in community pharmacy. Diabetes Metab Syndr. 2021;15(6):102303.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3